Sequential Intensive Treatment with the F-MACHOP Regimen (± Radiotherapy) and Autologous Stem Cell Transplantation for Primary Systemic CD30 (Ki-1)— Positive Anaplastic Large Cell Lymphoma in Adults

References

• Kadin M. E. Primary Ki‐1‐positive anaplastic large‐cell lymphoma: a distinct clinicopathologic entity. Ann. Oncol. 1994; 5(suppl. 1)S95–S30
   PubMedGoogle Scholar
• Stansfeld A. G., Diebold J., Kapanci Y., Kelenyi G., Lannert K., Mioduszewska O., Noel H., Rilke F., Sundstrom C., Van Unnik J. A. M., Wrightm H. D. Updated Kiel classification for lymphomas. Lancet 1988; 1: 292–293
   PubMed Web of Science ®Google Scholar
• Schwab U., Stein H., Gerdes J., Lenike H., Kirchner H., Schaadt M., Diehl V. Production of a monoclonal antibody specific for Hodgkin's and Sternberg‐Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 1982; 299: 65–67
   PubMed Web of Science ®Google Scholar
• Stein H., Mason D. Y., Gerdes J., O'Connor N., Wainscoat J., Pallesen G., Gatter K., Falini B., Delsol G., Lemke H., Schwarting R., Lennert K. The expression of the Hodgkin's disease antigen Ki‐1 in reactive and neoplastic lymphoid tissue: evidence that Reed‐Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–858
   PubMed Web of Science ®Google Scholar
• Schwarting R., Stein H. Cluster report CD30. Leitkocyte typing IV, W. Knapp, B. Dörken, W. R. Gilks, E. P. Rieber, R. E. Schmidt, H. Stein, A. E.G. von de Borne. Oxford University Press, Oxford 1989; 419
   Google Scholar
• Stein H., Gerds J., Tippelmann G., Dienemann D., Schwarting R., O'Connor N., Pileri S., Pallesen G., Delsol G. (1987) Ki‐l lymphoma: experimental and clinical findings. Third International Conference on Malignant Lymphoma, Lugano, June, 10–131987, abstract
   Google Scholar
• de Bruin P. C., Beljaards R. C., van Heerde P., Van Der Valk P., Noorduyn L. A., Van Krieken J. H., Kluin‐Nelemans J. C., Willemze R., Meijer C. J. Differences in clinical behaviour and immunophenotype between primary cutaneous and primary nodal anaplastic large cell lymphoma of T‐cell or null cell phenotype. Histopathology 1993; 23: 127–135
   PubMed Web of Science ®Google Scholar
• Kaudewitz P., Stein H., Dallenbach F., Ecken F., Bieber K., Burg G., Braun‐Falco O. Primary and secondary cutaneous Ki‐1 + (CD30) anaplastic large cell lymphomas. Am. J. Pathol. 1989; 135: 359–367
   PubMed Web of Science ®Google Scholar
• Beljaards R. C., Kaudewitz P., Berti E., Gianotti R., Neumann C., Rosm R., Paulli M., Meijer C. J., Willemze R. Primary cutaneous CD30‐positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favourable prognosis. A European Multicenter Study of 47 patients. Cancer 1993; 71: 2097–2104
   PubMed Web of Science ®Google Scholar
• Stein H., Herbst H., Anagnostopoulos I., Niedobitek G., Dallenbach F., Kratzach H. C. The nature of Hodgkin and Reed‐Sternberg cells, their association with EBV. and their relationship to anaplastic large cell lymphoma. Ann. Oncol. 1991; 2: 33–38
   PubMed Web of Science ®Google Scholar
• Pileri S., Mazza P., Zinzani P. L., Poggi S., Poletti G., Falini B., Tura S. Ki‐1 lymphoma and Hodgkin's disease. Haematologica 1989; 74: 333–335
   PubMedGoogle Scholar
• Chan J. K. C., Ng C. S., Hui P. K., Leung T. W., Lo E. S. F., Lau W. H., McGuire L. J. Anaplastic large cell Ki‐1 lymphoma. Delineation of two morphological types. Histopathology 1989; 15: 11–34
   PubMed Web of Science ®Google Scholar
• Agnarsson B. N., Kadin E. K. Ki‐1 positive large cell lymphoma. Am. J. Surg. Pathol. 1988; 12: 264–274
   PubMed Web of Science ®Google Scholar
• Rodriguez J., Pugh W., Romaguera J., Cabanillas F. Anaplastic Ki‐1+ large‐cell lymphoma. Cancer Investigation 1993; 11: 554–558
   PubMed Web of Science ®Google Scholar
• Tashiro K., Kikuchi M., Takeshita M., Yoshida T., Ohshima K. Clinicopathological study of Ki‐1‐positive lymphomas. Path. Res. Pract. 1989; 185: 461–467
   PubMed Web of Science ®Google Scholar
• Chott A., Kaserer K., Augustin I., Vesely M., Heinz R., Oehlinger W., Hanak H., Radaszkiewcz T. Ki‐1 positive large cell lymphoma. A clinicopathologic study of 41 cases. Am. J. Surg. Pathol. 1990; 14: 439–448
   PubMed Web of Science ®Google Scholar
• Nakamura S., Takagi N., Kojima M., Motoori T., Kitoh K., Osada H., Suzuki H., Ogura M., Kurita S., Oyama A., Ueda R., Takahashi T., Suck T. Clinicopathologic study of large cell anaplastic lymphoma (Ki‐1‐positive large cell lymphoma) among the Japanese. Cancer 1991; 68: 118–129
   PubMed Web of Science ®Google Scholar
• Penny R. J., Blaustein J. C., Longtine J. A., Pinkus G. S. Ki‐1‐positive large cell lymphomas, a heterogenous group of neoplasms. Cancer 1991; 68: 362–373
   PubMed Web of Science ®Google Scholar
• Greer J. P., Kinney M. C., Collins R. D., Salhany K. E., Wolff S. N., Hainsworth J. D., Flexner J. M., Stein R. S. Clinical features of 31 patients with Ki‐1 anaplastic large‐cell lymphoma. J. Clin. Oncol. 1991; 9: 539–547
   PubMed Web of Science ®Google Scholar
• Shulman L. N., Frisard B., Antin J. H., Wheeler C., Pinkus G., Magauran N., Mauch P., Nobles E., Mashal R., Canellos G., Tung N., Kadin M. Primary Ki‐1 anaplastic large‐cell lymphoma in adults: clinical characteristics and therapeutic outcome. J. Clin. Oncol. 1993; 11: 937–942
   PubMed Web of Science ®Google Scholar
• Pileri S., Bocchia M., Baroni C. D., Martelli M., Falini B., Sabattini E., Gherlinzoni F., Amadori S., Poggi S., Mazza P., Burgio V., Zinzani P. L., Melilli G., Benni M., Saragoni L., Martelli M., Stein H., Mandelli F., Tura S. Anaplastic large cell lymphoma (CD30+/Ki‐I+): results of a prospective clinico‐pathologic study of 69 cases. Br. J. Haematol. 1994; 86: 513–523
   PubMed Web of Science ®Google Scholar
• Romaguera J. E., Manning J. T., Jr., Tomos C. S., Rodriguez J., Brooks T. E., Pugh W. B., Ordonez N. G., Goodacre A. M., Cabanillas F. Long‐term prognostic importance of primary Ki‐1 (CD30) antigen expression and anaplastic morphology in adult patients with diffuse large‐cell lymphoma. Ann. Oncol. 1994; 5: 317–322
   PubMed Web of Science ®Google Scholar
• Tirelli U., Vaccher E., Zagonel V., Talamini R., Bernardi D., Tavia M., Gloghini A., Merola M. C., Monfardini S., Carbone A. CD30 (Ki‐1)‐positive anaplastic large‐cell lymphomas in 13 patients with and 27 patients without human immunodeficiency virus infection: the first comparative clinicopathologic study from a single institution that also includes 80 patients with other human immunodeficiency virus‐related systemic lymphomas. J. Clin. Oncol. 1995; 13: 373–380
   PubMed Web of Science ®Google Scholar
• Bitter M. A., Franklin W. A., Larson R. A., McKeithan T. W., Rubin C. M., Le Beau M. M., Stephens J. K., Vardiman J. W. Morphology in Ki‐1 (CD30)‐positive non‐Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t (2;5) (p23;q35). Am. J. Surg. Pathol. 1990; 14: 305–316
   PubMed Web of Science ®Google Scholar
• Salhany K. E., Collins R. D., Greer J. P., Kinney M. C. Long‐term survival in Ki‐1 lymphoma. Cancer 1991; 67: 516–522
   PubMed Web of Science ®Google Scholar
• Marosi C., Heinz R., Steger G., Fortelny A., Chott A., Hanak H., Radaszkiewicz T., Baur M., Kreiner G., Schwarzinger I. MACOP‐B treatment in patients with Ki‐1‐positive large‐cell anaplastic lymphoma. J. Cancer Res. Clin. Oncol. 1992; 118: 314–317
   PubMed Web of Science ®Google Scholar
• Harris N. L., Jaffe E. S., Stein H., Banks P. M., Chan K. C., Cleary M. L., Delsol G., De Wolf‐Peeters C., Falini B., Gatter K. C., Grogan T. M., Isaacson P. G., Knowles D. M., Mason D. Y., Muller‐Hermelink H. K., Pileri S. A., Piris M. A., Ralfkiaer E., Warnke R. A. A revised European‐American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• De Vita F., Di Grazia M., Orditura M., Saieva M. R., Catalano G. Autologous bone marrow transplantation in Ki‐1 lymphoma with poor prognosis. A case report. Recent Prog. Med. 1994; 85: 278–281
   PubMedGoogle Scholar
• Guglielmi C., Amadori S., Anselmo A. P., Baroni C. D., Biagini C., Cimino G., Papa G., Mandelli F. Sequential combination chemotherapy of high‐grade non‐Hodgkin's lymphoma with 5–Fluorouracil, Methotrexate, Cytosine‐Arabinoside, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (F‐MACHOP). Cancer Investigation 1987; 5: 159–169
   PubMed Web of Science ®Google Scholar
• Infanti L., Silvestri F., Fanin R., Salmaso F., Zaja F., Barillari G., Damiani D., Geromin A., Cerno M., Patriarca F., Baccarani M. The F‐MACHOP regimen in the treatment of high risk non‐Hodgkn's lymphomas: a single centre experience in 72 patients. Haematologica 1996, in press
   PubMedGoogle Scholar
• Carbone P. P., Kaplan H. S., Musshoff K., Smithers D. W., Tubiana M. Report of the Commettee on Hodgkin's Disease Staging Classification. Cancer Res. 1971; 31: 1860–1861
   PubMed Web of Science ®Google Scholar
• Oken M. M., Creech R. H., Tormey D. C., Horton J., Davis T. E., McFadden E. T., Carbone P. P. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 1982; 5: 649–655
   PubMed Web of Science ®Google Scholar
• The International Non‐Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non‐Hodgkin's Lymphoma. N. Engl. J. Med. 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Zaja F., Russo D., Silvestri F., Fanin R., Infanti L., Bendini M., Zuiani C., Englaro E., Cattaruzzi E., Guerra U. Computed tomography, magnetic resonance and 67‐Gllium scintigraphy for the imaging of residual lymphoma. Haematologica 1995; 80: 574–578
   PubMedGoogle Scholar
• Damiani D., Fanin R., Silvestri F., Grimaz S., Infanti L., Cerno M., Geromin A., Michieli M., Rinaldi C., Savignano C., Baccarani M. Randomized trial of autologous filgrastini‐primed bone marrow transplantation versus filgrastim‐mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood 1996, 1996, submitted
   PubMedGoogle Scholar
• Geromin A., Fanin R., Silvestri F., Damiani D., Cerno M., Sperotto A., Infanti L., Micheli M. G., Barillari G., Rinaldi C., Savignano C., Baccarani M. Autologous bone marrow transplantation and granulocyte colony‐stimulating factor: a safe procedure for treatment intensification of malignant lymphoma. Haematologica 1996, in press
   Google Scholar
• Fanin R., Silvestri F., Geromin A., Cerno M., Infanti L., Zaja F., Barillari G., Savignano C., Rinaldi C., Damiani D., Buffoli A., Biffoni F., Baccarani M. Primary systemic CD30 (Ki‐1)‐positive anaplastic large cell lymphoma of the adult: sequential intensive treatment with the F‐MACHOP regimen (± radiotherapy) and autologous bone marrow transplantation. Blood 1996; 87: 1243–1248
   PubMed Web of Science ®Google Scholar
• Fanin R., Geromin A., Silvestri F., Cerno M., Savignano C., Rinaldi C., Damiani D., Russo D., Baccarani M. Consolidation treatment in aggressive non‐Hodgkin's lymphoma with autologous bone marrow transplantation (Abstract). Bone Marrow Transplant 1995; 15(suppl. 2)S99
   PubMedGoogle Scholar
• Haoiun C., Lapage E., Gisselbrecht Ch., Coiffer B., Bosly A., Dupriel B., Nouvel C., Tilly H., Lederlin P., Biron P., Briere J., Gaulard Ph., Reyes F. Autologous bone marrow transplantation (ABMT) versus sequential chemotherapy for aggressive non‐Hodgkin's lymphoma (NHL) in first complete remission (CR): a study of 542 patients (LNH87–2 Protocol) (Abstract). Blood 1995; 86(suppl. 1)1816a
   Google Scholar
• Vitolo U., Cortellazzo S., Liberati A. M., Freilone R., Folda M., Bertini M., Botta B., Cimiani S., Locatelli F., Marmont F., Pizzuti M., Rossi A., Tiero P., Grignani F., Barbui T., Resegotti L. Intensified chemotherapy followed by myeloablative therapy and autologous stem cell transplantation (ASCT) as first line therapy in high risk diffuse large cell lymphoma (DLCL) (Abstract). Blood 1995; 86(suppl. 1)1819a
   Google Scholar
• Vose J. M., Bierrnan P. J., Anderson J., Bishop M. R., Kessinger A., Armitage J. O. Patients with diffuse aggressive non‐Hodgkin's lymphomas (NHL) transplanted within one year from initial diagnosis: improved outcome with transplantation planned as part of initial therapy (Abstract). Blood 1995; 86(suppl. 1)1820a
   PubMedGoogle Scholar
• Reiter A., Schrappe M., Tiemann M., Parwaresch R., Zimmermann M., Yakisan E., Dopfer R., Bucsky P., Mann G., Gadner H., Riehm H. Successful treatment strategy for Ki‐1 anaplastic large‐cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin‐Frankfurt‐Munster group studies. J. Clin. Oncol. 1994; 12: 899–908
   PubMed Web of Science ®Google Scholar
• Sandlund J. T., Pui C. K., Santana V. M., Mahmoud H., Roberts W. M., Morris S., Raimondi S., Ribeiro R., Crist W. M., Lin J. S., Mao I., Berard C. W., Hutchison E. Clinical features and treatment outcome for children with CD30+ large‐cell non‐Hodgkin's lymphoma. J. Clin. Oncol 1994; 12: 895–898
   PubMed Web of Science ®Google Scholar
• Zinzani P.L., Bendandi M., Martelli M., Falini B., Sabattini E., Amadori S., Gherlinzoni F., Martelli F., Mandelli F., Tura S., Pileri S. A. Anaplastic large‐cell lymphoma: clinical and prognostic evaluation of 90 adult patients. J. Clin. Oncol. 1996; 14: 955–962
   PubMed Web of Science ®Google Scholar